Asia Pacific Allergy最新文献

{"title":"The treatment efficacy of dupilumab in autosomal dominant hyper-immunoglobulin E syndrome with severe atopic dermatitis.","authors":"Weifeng Li, Qiqi Qi, Weipeng Wang, Dongqin Li","doi":"10.5415/apallergy.0000000000000121","DOIUrl":"10.5415/apallergy.0000000000000121","url":null,"abstract":"<p><p>Hyper-immunoglobulin E syndrome (HIES) is a primary immunodeficiency disease characterized by atopic dermatitis, recurrent skin and lung infections, and significantly elevated serum immunoglobulin E levels. Autosomal dominant and loss-of-function pathogenic variants in the <i>STAT3</i> gene are the most common causes of the disease and studies have shown that the presence of IL-4 receptor (IL-4R) is upregulated in patients with dominant-negative mutations in the <i>STAT3</i> gene expression. Dupilumab is a monoclonal antibody that targets the IL-4α receptor and improves the symptoms of atopic dermatitis by inhibiting IL-4 and IL-13. We used dupilumab to treat severe dermatitis in a patient with STAT3-HIES and achieved satisfactory results.</p>","PeriodicalId":8488,"journal":{"name":"Asia Pacific Allergy","volume":"14 1","pages":"39-41"},"PeriodicalIF":1.7,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10932477/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140118676","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A prospective observational study correlating possible novel biomarkers with disease severity and antihistamine response in chronic spontaneous urticaria.","authors":"Divya Bhatia, Hitaishi Mehta, Anuradha Bishnoi, Niharika Srivastava, Keshavamurthy Vinay, Davinder Parsad, Muthu Sendhil Kumaran","doi":"10.5415/apallergy.0000000000000132","DOIUrl":"10.5415/apallergy.0000000000000132","url":null,"abstract":"<p><strong>Background: </strong>Role of complement fraction 5a (C5a), interleukin (IL)-9, and apolipoprotein (apo) A-IV as biomarkers of disease severity and antihistamine response in chronic spontaneous urticaria (CSU) remains elusive.</p><p><strong>Objective: </strong>To identify the role of C5a, IL-9, and apo A-IV as potential biomarkers in predicting disease severity and antihistamine response in CSU patients.</p><p><strong>Methods: </strong>This was a prospective observational study of 95 patients and 42 controls. Serum analysis of C5a, IL-9, and apo A-IV was done using enyzme linked immunosorbent assay kits. Also, serum IgE and anti-thyroid peroxidase (TPO) levels were assessed in all patients. All patients were started on oral levocetirizine 5 mg at baseline and dose was titrated upwards to maximum of 20 mg based on response. Patients were categorized into antihistamine responders or nonresponders as per their disease response. Serological markers, serum IgE, and anti-TPO were correlated with baseline disease severity and antihistamine response.</p><p><strong>Results: </strong>C5a levels were significantly higher in cases as compared to controls (<i>P</i> = 0.004). Significantly higher IL-9 levels were observed in antihistamine responders than nonresponders (<i>P</i> = 0.008). Baseline urticaria severity demonstrated a statistically significant positive and negative correlations with IL-9 (<i>ρ</i> = 0.277, <i>P</i> = 0.007) and apo A-IV (<i>ρ</i> = -0.271, <i>P</i> = 0.008) levels, respectively. Levels of serum IgE (<i>P</i> = 0.031) and anti-TPO (<i>P</i> = 0.039) were significantly higher in antihistamine nonresponders compared to responders.</p><p><strong>Conclusions: </strong>IL-9 and apo A-IV might be potential novel biomarkers to predict urticaria severity. Higher IL-9 might be a predictor of antihistamine response. Elevated anti-TPO and serum IgE might predict poor antihistamine response.</p>","PeriodicalId":8488,"journal":{"name":"Asia Pacific Allergy","volume":"14 1","pages":"5-11"},"PeriodicalIF":1.7,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10932479/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140118670","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correlation of <i>Blomia tropicalis</i>-specific immunoglobulin epsilon profiles with family history of atopy in a Filipino population.","authors":"Chanie Y Patanindagat, Jamie Ezra B Tarun, Ryla Jasmine T Pajaro, Jhon Jerald D Pintucan, Patricia Nichole M Quilang, Maureen B Sabit, John Donnie A Ramos","doi":"10.5415/apallergy.0000000000000133","DOIUrl":"10.5415/apallergy.0000000000000133","url":null,"abstract":"<p><strong>Background: </strong>House dust mites are the major source of indoor allergens in the tropical and subtropical regions with <i>Blomia tropicalis</i> (Bt) allergens as one of the leading causative agents of sensitization among patients from the tropics. Despite the clinical importance of Bt in various populations, its allergenicity remains unclear among Filipino allergic patients.</p><p><strong>Objective: </strong>This study determined the sensitization profiles of allergic Filipinos against Bt allergens and its correlation with atopy.</p><p><strong>Methods: </strong>Total immunoglobulin epsilon (IgE) (n = 960), Bt-specific IgE (n = 247), and <i>Blomia tropicalis</i> 5 (Blo t 5)-specific IgE (n = 87) profiles of allergic and nonallergic subjects were measured through enzyme-linked immunosorbent assay (ELISA). Point-biserial correlation coefficient was used to determine the association between Bt-specific IgE levels and selected demographics. Inhibition ELISA was performed to measure the inhibition capacity of recombinant Blo t 5 (rBlo t 5) against Bt allergen extracts.</p><p><strong>Results: </strong>Mean total IgE levels of allergic cases (n = 171) were significantly higher (<i>P</i> < 0.001) compared to the mean IgE levels of nonallergic controls (n = 76). Among allergic subjects, 58% were sensitized to Blo t extract and 80% of which were sensitized to rBlo t 5 allergen. A positive correlation was observed between Bt-specific IgE and family history of atopic disease (<i>P</i> = 0.031). Inhibition assay revealed that 54% mean reactivity of 7 plasma samples was caused by rBlo t 5, validating that rBlo t 5 is a major allergen in Bt.</p><p><strong>Conclusions: </strong>This study has shown the importance of Bt as an allergen source that sensitizes atopic Filipino subjects. Hence, inclusion of Bt allergen extract and rBlo t 5 in the panel for allergy diagnosis and immunotherapy in Filipino populations is strongly recommended.</p>","PeriodicalId":8488,"journal":{"name":"Asia Pacific Allergy","volume":"14 1","pages":"12-20"},"PeriodicalIF":1.6,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10932478/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140118673","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Does omalizumab increase the risk of malignancy? A retrospective case-control study in a single tertiary hospital.","authors":"Hyun Jee Kim, Suh Young Lee, Sang-Heon Cho, Hye-Ryun Kang","doi":"10.5415/apallergy.0000000000000137","DOIUrl":"10.5415/apallergy.0000000000000137","url":null,"abstract":"","PeriodicalId":8488,"journal":{"name":"Asia Pacific Allergy","volume":"14 1","pages":"42-43"},"PeriodicalIF":1.7,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10932485/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140118674","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Anti-thymic stromal lymphopoietin monoclonal antibody in patients with chronic rhinosinusitis with nasal polyps (DUBHE): Rationale and design of a multicenter, randomized, double-blind, placebo-controlled study.","authors":"Shen Shen, Mu Xian, Bing Yan, Feng Lan, Chengshuo Wang, Luo Zhang","doi":"10.5415/apallergy.0000000000000135","DOIUrl":"10.5415/apallergy.0000000000000135","url":null,"abstract":"<p><strong>Background: </strong>Chronic rhinosinusitis with nasal polyps (CRSwNP) has a complex pathogenesis and is difficult to treat, which brings a huge economic burden to society. Despite all the progress in the treatment of CRSwNP, some patients with CRSwNP still experience recurrence. Therefore, there is an urgent need to develop novel drugs and treatments for CRSwNP. Thymic stromal lymphopoietin (TSLP) is produced by epithelial cells and mediates type 2 and nontype 2 inflammation through various downstream cellular immune and inflammatory pathways. Anti-TSLP treatment with tezepelumab has been proven to be effective in treating patients with uncontrolled asthma, regardless of their peripheral blood eosinophil levels being low or high. However, there is no relevant research on the usage of anti-TSLP monoclonal antibodies for the treatment of uncontrolled CRSwNP.</p><p><strong>Objective: </strong>This is the first phase Ib/IIa study for subjects with uncontrolled CRSwNP, aiming to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and preliminary efficacy of multiple ascending doses (MAD) of anti-TSLP monoclonal antibody.</p><p><strong>Methods: </strong>The DUBHE is a multicenter, randomized, double-blind, placebo-controlled, phase Ib/IIa clinical study. The study will be composed of 3 periods: a screening/run-in period of 4 weeks, a treatment period of 52 weeks (16 weeks of double-blind treatment period +36 weeks of open-label treatment period), and a safety follow-up period of 12 weeks. No more than 113 subjects with uncontrolled CRSwNP will be divided into 4 groups to receive different doses of CM326 or placebo treatments (55 mg every two weeks [Q2W] group, 110 mg Q2W group, 220 mg Q2W group, and 220 mg every four weeks [Q4W] group). Enrolled patients will be stratified by tissue eosinophil count (TEC).</p><p><strong>Results: </strong>The safety of the monoclonal antibody that targets TSLP in uncontrolled CRSwNP and its preliminary efficacy at 16 weeks of treatment.</p><p><strong>Conclusion: </strong>In this study, for the first time, the safety and preliminary efficacy of MAD of CM326 will be verified. The efficacy of CM326 in patients with eosinophilic CRSwNP (TEC ≥55/high power field [HPF]), as well as noneosinophilic CRSwNP (TEC <55/HPF) will be testified.</p><p><strong>Trial registration: </strong>NCT05324137.</p>","PeriodicalId":8488,"journal":{"name":"Asia Pacific Allergy","volume":"14 1","pages":"26-31"},"PeriodicalIF":1.7,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10932481/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140118671","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Biomarkers in allergen immunotherapy: Focus on eosinophilic inflammation.","authors":"Chang-Keun Kim, Zak Callaway, Jin-Sung Park, Ruby Pawankar, Takao Fujisawa","doi":"10.5415/apallergy.0000000000000129","DOIUrl":"10.5415/apallergy.0000000000000129","url":null,"abstract":"<p><p>Asthma and allergic rhinitis (AR) are 2 of the most common chronic inflammatory disorders and they appear to be on the rise. Current pharmacotherapy effectively controls symptoms but does not alter the underlying pathophysiology. Allergen immunotherapy (AIT) is an evidence-based therapy for asthma and AR and has been recognized as the only therapeutic method that actually modifies the allergic disease process. There is a lack of objective markers that accurately and reliably reflect the therapeutic benefits of AIT. A biomarker indicating patients that would benefit most from AIT would be invaluable. Eosinophilic inflammation is a cardinal feature of many allergic diseases. Biomarkers that accurately reflect this inflammation are needed to better diagnose, treat, and monitor patients with allergic disorders. This review examines the current literature regarding AIT's effects on eosinophilic inflammation and biomarkers that may be used to determine the extent of these effects.</p>","PeriodicalId":8488,"journal":{"name":"Asia Pacific Allergy","volume":"14 1","pages":"32-38"},"PeriodicalIF":1.6,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10932480/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140118672","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence of allergic sensitization to <i>Platanus occidentalis</i> among adults with allergic rhinitis: A multicenter study.","authors":"Martín Bedolla-Barajas, Javier Domínguez-Morales, Ilse Mariana Loya-Barriga, Angie Bedolla-Pulido, Luis Alfredo Jiménez-Huerta, Jaime Morales-Romero","doi":"10.5415/apallergy.0000000000000127","DOIUrl":"10.5415/apallergy.0000000000000127","url":null,"abstract":"<p><strong>Background: </strong>In the Americas there are few studies that have evaluated the frequency of allergic sensitization to <i>Platanus occidentalis</i> or sycamore pollen in adult patients with allergic rhinitis (AR).</p><p><strong>Objective: </strong>To determine the prevalence of allergic sensitization to <i>P. occidentalis</i> and to identify factors associated with its presentation.</p><p><strong>Methods: </strong>A cross-sectional study was carried out in 3 centers distributed in the northwest, west, and southeast of Mexico. Allergic sensitization to <i>P. occidentalis</i> was determined with a skin prick test. Prevalence and 95% confidence intervals (CI) were estimated.</p><p><strong>Results: </strong>A total of 404 patients were included, women were 233 (57.7%); the age mean was 33.8 ± 12.9 years. The overall prevalence of sensitization to <i>P. occidentalis</i> was 20.8% (95% CI, 17.1%-25.0%); in the northwestern: 15.9% (95% CI, 9.6%-25.1%); in the western: 21.8% (95% CI, 15.4%-29.9%); and in the southeastern: 22.4% (95% CI, 17.1%-38.8%). Multivariate analysis showed to the following allergens as factors associated with sycamore allergic sensitization: tree pollens (OR, 3.19; <i>P</i> = 0.001), weeds (OR, 2.49; <i>P</i> = 0.004), fungi (OR, 1.96; <i>P</i> = 0.014), and dog or cat epitheliums (OR, 1.88; <i>P</i> = 0.018).</p><p><strong>Conclusion: </strong>Allergic sensitization to <i>P. occidentalis</i> pollen in AR patients is not an infrequent event; consequently, we recommend doing the challenge test in all patients with this allergen, especially in those regions where the tree is present.</p>","PeriodicalId":8488,"journal":{"name":"Asia Pacific Allergy","volume":"14 1","pages":"21-25"},"PeriodicalIF":1.7,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10932483/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140118675","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Activities and concentration of alpha-1 antitrypsin and cystatin C in serum from patients with house dust mite asthma","authors":"Mailani Dwi Hidayati, F. C. Iswanti, Samsuridjal Djauzi, Sukamto Koesnoe, Mohamad Sadikin","doi":"10.5415/apallergy.0000000000000124","DOIUrl":"https://doi.org/10.5415/apallergy.0000000000000124","url":null,"abstract":"Background: The proteolytic activities of house dust mite (HDM) allergens are involved in the pathogenesis of asthma by cleaving T-junction protein complexes, increasing the permeability of airway epithelial cells, and enabling the allergens to reach the interstitial tissue. The human body contains natural protease inhibitors such as alpha-1 antitrypsin (AAT) with antiserine protease activity and cystatin C with anticysteine protease activity. Objective: This study aimed to investigate the behavior of serum AAT and cystatin C levels in patients with HDM-allergic asthma. Methods: Ten individuals with HDM-allergic asthma and 10 healthy volunteers participated in a cross-sectional study. The serum AAT and cystatin C inhibitory activities were measured using enzymatic assays. ELISA was used to determine the serum AAT and cystatin C concentrations. Results: Serum AAT inhibitory activity (P = 0.445; P > 0.05), AAT concentration (P = 0.290; P > 0.05), and cystatin C concentration (P = 0.419; P > 0.05) did not significantly differ between the patient and control groups. However, serum cystatin C inhibitory activity in the asthmatic patient group was significantly higher than in the healthy subjects (P = 0.001; P < 0.05). There was no correlation between AAT inhibitory activity and AAT concentration or between cystatin C inhibitory activity and cystatin C concentration. Conclusion: These findings suggest that serum cystatin C activity is involved in asthma pathogenesis. Additional research is required to address this issue.","PeriodicalId":8488,"journal":{"name":"Asia Pacific Allergy","volume":"335 7","pages":"158 - 163"},"PeriodicalIF":1.7,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138625852","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"APAAACI 2023 International Conference: The innovation revolution in allergy, asthma, and immunology","authors":"B. Thong, R. Pawankar","doi":"10.5415/apallergy.0000000000000130","DOIUrl":"https://doi.org/10.5415/apallergy.0000000000000130","url":null,"abstract":"","PeriodicalId":8488,"journal":{"name":"Asia Pacific Allergy","volume":" 11","pages":"139 - 141"},"PeriodicalIF":1.7,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138619722","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Application of nasal irrigation in the treatment of chronic rhinosinusitis","authors":"Ling Jin, K. Fan, Shaoqing Yu","doi":"10.5415/apallergy.0000000000000120","DOIUrl":"https://doi.org/10.5415/apallergy.0000000000000120","url":null,"abstract":"Nasal irrigation (NI) for the local treatment of chronic rhinosinusitis (CRS) has some specificity due to the deep anatomical site of the sinuses. The purpose of this review is to help standardize the application of NI in healthcare practice, improve the prevention and treatment of CRS, and facilitate further research on the local treatment of CRS in the future. We searched the PubMed database for 342 articles in the last decade, using the keywords “saline nasal irrigation” and “chronic rhinosinusitis.” We summarize the studies on the mechanism of action, rinsing solution, rinsing apparatus, and rinsing method of NI for CRS. NI plays an important role in the treatment of CRS, and it is a beneficial low-risk treatment. Isotonic saline is the most accepted flushing solution, and large-volume low-pressure flushing bottles are the flushing devices with the best flushing effect and are generally tolerated by patients. Phage, colloidal silver, and hydrogen can be further studied as components of rinses. NI plays an important role in the treatment of CRS, and it is a beneficial low-risk treatment. Further high-quality and expanded sample size studies on other flushing solutions, flushing head position, flushing frequency, and treatment courses are still needed, and lessons learned in practice.","PeriodicalId":8488,"journal":{"name":"Asia Pacific Allergy","volume":" 35","pages":"187 - 198"},"PeriodicalIF":1.7,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138616308","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}